You are here: Home » News-CM » Companies » News
Business Standard

Alembic Pharmaceuticals receives USFDA approval for Tizanidine Hydrochloride Capsules

Capital Market 

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tizanidine Hydrochloride Capsules, 2 mg, 4 mg, and 6 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Zanaflex Capsules, 2 mg, 4 mg, and 6 mg, of Covis Pharma B.

V. Tizanidine hydrochloride is a central alpha-2-adrenergic agnist indicated for the management of spasticity.

Tizanidine Hydrochloride Capsules, 2 mg, 4 mg, and 6 mg have an estimated market size of US$ 28 million for twelve months ending September 2019 according to IQVIA.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, January 15 2020. 11:18 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU